5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF)

Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF)

Chronic Myeloproliferative Neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by the autonomous, unregulated proliferation of one or more myeloid lineages (granulocytic, erythroid, or megakaryocytic) in the bone marrow. Unlike myelodysplastic syndromes, hematopoiesis in MPNs is effective, leading to marrow hypercellularity (panmyelosis) accompanied by elevated numbers of mature functional cells in the peripheral circulation (cytoses: leukocytosis, erythrocytosis, and/or thrombocytosis).

All MPNs share clinical and biological tendencies:

1. Origin in a multipotent hematopoietic stem cell.
2. Autonomous proliferation independent of normal growth factor regulation.
3. Extramedullary hematopoiesis (myeloid metaplasia) primarily involving the spleen and liver, resulting in splenomegaly and hepatomegaly.
4. Variable potential to undergo fibrotic transformation (spent phase / myelofibrosis) or transform into Acute Myeloid Leukemia (AML) (blast phase/crisis).

                     CHRONIC MYELOPROLIFERATIVE NEOPLASMS
                                      │
     ┌────────────────────────────────┼────────────────────────────────┐
     ▼                                ▼                                ▼
[ CML ]                            [ PV ]                      [ ET & PMF ]
• t(9;22) BCR::ABL1             • JAK2 V617F (>95%)            • JAK2 V617F (50-60%)
• Full granulocyte spectrum       or Exon 12 (3-5%)            • CALR Exon 9 (25-30%)
• Absolute Basophilia           • Suppressed Serum EPO         • MPL W515 (3-5%)
• LAP Score < 20                • Panmyelosis & Plethora       • ET: Plts ≥450 × 10^9/L
• Responsive to TKIs            • Aquagenic Pruritus           • PMF: Dacrocytes & Fibrosis

---

1. Chronic Myeloid Leukemia (CML), $BCR::ABL1$-Positive

Chronic Myeloid Leukemia is a clonal myeloproliferative neoplasm originating in a pluripotent stem cell and accounting for approximately 15% of all adult leukemias. It occurs predominantly in adults aged 40 to 60 years, with a slight male predominance.

Molecular Genetics & The Philadelphia Chromosome

CML is cytogenetically defined by the Philadelphia ($Ph$) chromosome, a reciprocal balanced translocation between the long arms of chromosomes 9 and 22: $\text{t}(9;22)(\text{q}34.1;\text{q}11.2)$.

• Molecular Fusion: The $ABL1$ proto-oncogene (a non-receptor tyrosine kinase on chromosome 9q34) is translocated to the Breakpoint Cluster Region ($BCR$) gene on chromosome 22q11.2.
• Chimeric Oncoprotein: The resulting derivative chromosome 22, $\text{der}(22)$, contains the chimeric $BCR::ABL1$ fusion gene, which encodes a constitutively active p210 kDa tyrosine kinase protein ($e13a2$ or $e14a2$ transcript splice junctions).
• Pathophysiologic Action: The p210 oncoprotein continuously phosphorylates downstream signaling effectors (JAK-STAT, PI3K/Akt, RAS/MAPK), driving unchecked granulocyte proliferation, suppressing apoptosis, and impairing stromal cell adhesion.

  Chromosome 9                Chromosome 22               Philadelphia Chromosome
  ┌───────────┐               ┌───────────┐                     der(22)
  │   ABL1    │ (9q34.1)      │    BCR    │ (22q11.2)         ┌─────────┐
  └─────┬─────┘               └─────┬─────┘                   │BCR::ABL1│
        │                           │                         └────┬────┘
        └───────────────────────────┴──────────────────────────────┘
                                    │
                                    ▼
                  Constitutively Active p210 Tyrosine Kinase
                  • Uncontrolled Granulocyte Proliferation
                  • Inhibition of Normal Apoptosis
                  • Defective Cellular Adhesion

Peripheral Blood & Bone Marrow Morphology

• Marked Leukocytosis: Total leukocyte count is dramatically elevated, typically ranging from $50,000\text{ to }>200,000/\mu\text{L}$ (often $>100 \times 10^9/\text{L}$).
• Complete Granulocytic Maturation Spectrum: The peripheral blood smear displays every stage of granulocytic development (myeloblasts, promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils). A characteristic "bimodal peak" (dual peak) is observed, in which myelocytes and segmented neutrophils represent the two largest numerical populations.
• Absolute Basophilia: A cardinal diagnostic hallmark present in virtually 100% of CML patients. Absolute eosinophilia is also frequently present.
• Platelet Count: Normal to markedly elevated (thrombocytosis $>450 \times 10^9/\text{L}$ in up to 50% of cases).
• Bone Marrow: Strikingly hypercellular ($90\text{--}100%$ cellularity) with marked myeloid hyperplasia; the Myeloid-to-Erythroid (M:E) ratio is characteristically elevated to $10:1\text{ to }>25:1$ (normal is $1.5:1\text{ to }3.0:1$). Pseudo-Gaucher cells (sea-blue histiocytes filled with glucocerebroside from massive cell turnover) are commonly seen.

Leukocyte Alkaline Phosphatase (LAP / NAP) Scoring

The LAP score (Neutrophil Alkaline Phosphatase score) is an essential cytochemical discriminator in the evaluation of marked granulocytosis:

• Principle: Fresh peripheral blood smears are stained using a naphthol AS-BI phosphate substrate coupled with a diazonium salt (Fast Red Violet LB). 100 mature segmented neutrophils and bands are scored on a scale from 0 to 4+ based on the intensity and density of precipitated cytoplasmic azo dye granules (theoretical score: 0 to 400; normal adult reference range: 20 to 100).
• CML Profile: The LAP score is markedly subnormal or decreased ($<15\text{--}20$, frequently 0 to 5) because leukemic granulocytes lack functional alkaline phosphatase in their secondary granules.
• Leukemoid Reaction Distinction: A reactive leukemoid response (triggered by severe bacterial sepsis, acute hemolysis, or burns) produces toxic granulation, Döhle bodies, and a markedly elevated LAP score ($>100\text{ to }>250$), with an absence of basophilia and no $BCR::ABL1$ fusion.

Clinical Phases of CML

CML naturally progresses through three sequential clinical phases:

1. Chronic Phase (CP): Characterized by $<10%$ blasts in peripheral blood and bone marrow. Patients respond well to standard medical management.
2. Accelerated Phase (AP): Defined by $10\text{--}19%$ blasts in peripheral blood or bone marrow, peripheral blood basophils $\ge 20%$, persistent thrombocytopenia ($<100 \times 10^9/\text{L}$) or thrombocytosis ($>1000 \times 10^9/\text{L}$) unresponsive to therapy, increasing splenomegaly, and cytogenetic clonal evolution (e.g., secondary $Ph$ chromosome, trisomy 8, isochromosome 17q).
3. Blast Phase / Blast Crisis (BP): Defined by $\ge 20%$ blasts in peripheral blood or bone marrow, or presence of extramedullary blast proliferation. Approximately $70%$ transform into Acute Myeloid Leukemia (AML) and $30%$ transform into Acute Lymphoblastic Leukemia (ALL). This dual lineage potential confirms that the original neoplastic transforming event occurs in a pluripotent hematopoietic stem cell.

Targeted Molecular Therapy & Monitoring

First-line therapy utilizes Tyrosine Kinase Inhibitors (TKIs):

• First-Generation: Imatinib mesylate (Gleevec), a competitive inhibitor of the ATP-binding pocket on the ABL1 kinase domain.
• Second/Third-Generation: Dasatinib, Nilotinib, Bosutinib, and Ponatinib (the latter specifically overcomes the refractory $T315I$ gatekeeper mutation, where threonine is replaced by bulky isoleucine).
• Molecular Monitoring: Monitored via quantitative reverse-transcription PCR (RT-qPCR) measuring $BCR::ABL1$ transcript ratios on the International Scale ($IS$). Major Molecular Response (MMR / $MR^{3.0}$) is defined as $BCR::ABL1 / \text{control gene} \le 0.1%$ (a 3-log reduction from standardized baseline).

---

2. Polycythemia Vera (PV)

Polycythemia Vera is a clonal MPN characterized by the autonomous, uncontrolled overproduction of morphologically normal red blood cells (absolute erythrocytosis), accompanied to varying degrees by granulocytic and megakaryocytic proliferation (panmyelosis).

Molecular Genetics: The $JAK2$ Mutations

Over $95%$ of PV patients harbor the somatic $JAK2$ V617F mutation in exon 14 of the Janus Kinase 2 gene (chromosome 9p24). This mutation involves a single-base substitution (G1849T) causing a valine-to-phenylalanine substitution at amino acid position 617 within the auto-inhibitory pseudokinase domain ($JH2$). This disrupts negative regulation, locking the kinase domain ($JH1$) into a constitutively active state. The remaining $3\text{--}5%$ of PV patients carry somatic gain-of-function $JAK2$ exon 12 mutations (e.g., $K539L$, insertions/deletions).

                 JAK2 V617F MOLECULAR ACTIVATION MECHANISM

 Normal JAK2:       [ Kinase JH1 ] ◄─── Auto-inhibited by ───► [ Pseudokinase JH2 ]
                                                               (Regulated by EPO)

 Mutant V617F:      [ Kinase JH1 ] ◄─── Loss of Inhibition ──► [ Mutant Val617Phe ]
                                                               (Constitutively ON)
                                         │
                                         ▼
                     STAT5 / STAT3 Phosphorylation & Dimerization
                                         │
                                         ▼
                     Autonomous, EPO-Independent Erythropoiesis

WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires meeting all 3 major criteria, or the first 2 major criteria plus the minor criterion:

• Major Criterion 1: Elevated hemoglobin ($>16.5\text{ g/dL}$ in men; $>16.0\text{ g/dL}$ in women), or hematocrit ($>49%$ in men; $>48%$ in women), or direct demonstration of increased red cell mass ($>25%$ above mean normal).
• Major Criterion 2: Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) involving prominent erythroid, granulocytic, and pleomorphic megakaryocytic proliferation.
• Major Criterion 3: Presence of the $JAK2$ V617F or $JAK2$ exon 12 mutation.
• Minor Criterion: Subnormal / suppressed serum Erythropoietin (EPO) level.

Clinical Hallmarks & Laboratory Findings

• Suppressed Serum EPO: Autonomous erythroid proliferation exerts negative feedback on renal peritubular interstitial cells, dropping serum EPO to near-zero levels. This is the most crucial laboratory test distinguishing PV from secondary polycythemia (where hypoxemia, sleep apnea, high altitude, or EPO-secreting renal tumors drive high serum EPO).
• Aquagenic Pruritus: Severe, intractable generalized itching without visible rash occurring after contact with warm water (bathing/showering), mediated by abnormal histamine and prostaglandin release from clonal basophils and mast cells.
• Hyperviscosity & Thrombosis: High hematocrit markedly increases blood viscosity, producing headache, dizziness, visual disturbances, plethora (ruddy cyanosis of face/palms), and high risk for arterial and venous thrombosis (e.g., Budd-Chiari syndrome / hepatic vein thrombosis, portal vein thrombosis, stroke, myocardial infarction).
• Elevated LAP Score: Typically elevated ($>100$).
• Iron Deficiency: Total-body iron is consumed by the massive expanding red cell mass; therapeutic phlebotomy induces microcytic hypochromic red cell indices ($MCV < 75\text{ fL}$) with low serum ferritin.

---

3. Essential Thrombocythemia (ET)

Essential Thrombocythemia is a clonal MPN characterized by sustained, isolated overproduction of platelets in the peripheral blood ($>450 \times 10^9/\text{L}$) secondary to autonomous megakaryocyte proliferation, without prominent granulocytic or erythroid expansion.

Molecular Drivers

Three mutually exclusive driver mutations occur in ET:

1. $JAK2$ V617F: Present in $50\text{--}60%$ of cases; associated with older age, higher hemoglobin, and higher thrombotic risk.
2. Calreticulin ($CALR$) Exon 9 Mutations: Present in $25\text{--}30%$ of cases (predominantly 52-bp deletion [Type 1] or 5-bp insertion [Type 2]). Mutant CALR binds to the extracellular domain of the Thrombopoietin Receptor (MPL), driving continuous downstream activation. $CALR$-mutant patients tend to be younger, have higher platelet counts, and carry a lower risk of thrombosis.
3. Thrombopoietin Receptor ($MPL$) Mutations: Present in $3\text{--}5%$ of cases (primarily $MPL$ W515L/K).
4. Triple-Negative ET: Approximately $10%$ lack all three driver mutations.

Diagnostic Hallmarks & Smear Findings

• Platelet Count: Sustained elevation $\ge 450 \times 10^9/\text{L}$ (often $1,000,000\text{ to }>2,000,000/\mu\text{L}$).
• Peripheral Blood Smear: Striking thrombocytosis with giant, bizarre platelets, platelet aggregates, and megakaryocyte cytoplasmic fragments. Erythrocyte and leukocyte morphology are generally normal.
• Bone Marrow Biopsy: Hypercellular marrow showing a dramatic increase in large, mature, deeply hyperlobated ("staghorn" or "cloud-like") megakaryocytes distributed in loose clusters throughout the parenchyma, without significant granulocytic hyperplasia or reticulin fibrosis.
• Clinical Paradox: Patients experience both microvascular thrombosis (e.g., erythromelalgia: burning pain, erythema, and warmth in the hands and feet relieved by aspirin) and paradoxical bleeding. When the platelet count exceeds $1,000,000\text{ to }1,500,000/\mu\text{L}$, massive platelet surface area adsorbs and consumes high-molecular-weight von Willebrand factor multimers, causing an Acquired von Willebrand Syndrome.

---

4. Primary Myelofibrosis (PMF)

Primary Myelofibrosis (also termed Chronic Idiopathic Myelofibrosis or Agnogenic Myeloid Metaplasia) is a clonal MPN characterized by atypical megakaryocytic hyperplasia and the secondary deposition of extensive collagenous and reticulin connective tissue in the bone marrow stroma, leading to stem cell displacement, extramedullary hematopoiesis, and severe constitutional symptoms.

Pathophysiology of Stromal Fibrosis

The bone marrow fibrosis in PMF is not a primary clonal defect of fibroblasts; the fibroblasts are normal, non-clonal, polyclonal reactive cells. Instead, clonal megakaryocytes and monocytes synthesize and release excessive quantities of fibrogenic and angiogenic growth factors:

• Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-$\beta$ (TGF-$\beta$): Stimulate stromal fibroblasts to synthesize and deposit excessive Type I, Type III collagen, and reticulin fibers.
• Basic Fibroblast Growth Factor (bFGF) and VEGF: Induce marked intramedullary neo-angiogenesis.

                 PRIMARY MYELOFIBROSIS PATHOPHYSIOLOGIC CASCADE

 Clonal HSC Mutation (JAK2 / CALR / MPL) ──► Megakaryocytic Clonal Hyperplasia
                                                      │
                                                      ▼
                                     Intramedullary Release of Cytokines
                                         (PDGF, TGF-β, bFGF, VEGF)
                                                      │
                                                      ▼
                                     Polyclonal Fibroblast Activation
                                                      │
                                                      ▼
                                     Progressive Marrow Fibrosis (MF 0-3)
                                                      │
         ┌────────────────────────────────────────────┴────────────────────────────────────────────┐
         ▼                                                                                         ▼
"Dry Tap" on Bone Marrow Aspiration                                                     Extramedullary Hematopoiesis
• Mandatory Core Biopsy                                                                 • Massive Splenomegaly & Hepatomegaly
• Silver Stain: Reticulin Fibrosis                                                      • Leukoerythroblastic Peripheral Smear
• Trichrome: Collagen Fibrosis                                                            (Dacrocytes, NRBCs, Immature Granulocytes)

Diagnostic & Laboratory Profile

• Bone Marrow Examination: Bone marrow aspiration characteristically results in a "dry tap" (punctio sicca) because dense reticulin and collagen fibers trap cells and prevent aspiration. A trephine core biopsy is mandatory for diagnosis, demonstrating atypical megakaryocyte clusters with dense reticulin fibrosis (Gomori silver stain) or coarse collagen fibrosis (Masson trichrome stain), graded from MF-0 to MF-3.
• Leukoerythroblastic Peripheral Smear: As the fibrosed marrow can no longer support normal release, hematopoiesis shifts to the spleen and liver (extramedullary hematopoiesis), resulting in massive splenomegaly. Squeezing through rigid fibrotic marrow sinuses and splenic cords causes cellular distortion, producing the pathognomonic leukoerythroblastic picture:
  1. Dacrocytes (Teardrop Erythrocytes): Deformed red blood cells shaped like pear or tear drops.
  2. Nucleated Red Blood Cells (NRBCs): Circulating orthochromic and polychromatophilic normoblasts.
  3. Immature Granulocytic Precursors: Myelocytes, metamyelocytes, and promyelocytes.
  4. Giant Dysplastic Platelets and circulating dwarf megakaryocyte fragments.
• Driver Mutations: $JAK2$ V617F ($55\text{--}60%$), $CALR$ exon 9 ($25\text{--}30%$), and $MPL$ W515 ($5\text{--}8%$). Triple-negative PMF (~10%) carries the highest risk of rapid leukemic transformation and shortest overall survival.

---

5. Comprehensive Comparative Matrix of Classic MPNs